M7824
甲氨蝶呤
别名:
甲氨蝶呤, (+)-氨甲蝶呤, 4-氨基-N10-甲基巯基-L-谷氨酸, MTX, 氟安定, 氨甲叶酸, 氨甲喋呤
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H22N8O5
化学文摘社编号:
分子量:
454.44
EC Number:
200-413-8
UNSPSC Code:
41116107
NACRES:
NA.21
Beilstein/REAXYS Number:
70669
MDL number:
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChI key
FBOZXECLQNJBKD-ZDUSSCGKSA-N
SMILES string
CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O
biological source
synthetic
form
powder
suitability
suitable for manufacturing use
storage temp.
−20°C
Quality Level
Gene Information
human ... DHFR(1719)
正在寻找类似产品? 访问 产品对比指南
General description
我们用于生物制药加工的SAFC® 系列优质原料经过严格的质量控制流程，配合记录文件和技术专长帮助我们的客户达到M-Clarity Program规定的要求。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料，而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力，以最佳的法规支持和服务简化您的产品认证。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料，而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力，以最佳的法规支持和服务简化您的产品认证。
抑制胸苷酸合成酶，是一种非选择性的嘌呤从头合成抑制剂，具有显著的毒性特征，包括肝毒性、肺炎和骨髓抑制。强效叶酸拮抗剂。在HL-60人白血病细胞中诱导凋亡。还可用作抗肿瘤剂。
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1
target_organs
Liver,Bone marrow
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Kalle Jyri Aaltonen et al.
The Journal of rheumatology, 42(3), 372-378 (2015-01-17)
Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and infections. The objective of our study was to assess the incidence of serious
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持